Educational Events & Programs
NCCN Oncology Policy Program
The NCCN Oncology Policy Program was initiated in 2009 to allow opportunities for discussion among oncology stakeholders to address relevant health policy concerns. The NCCN Oncology Policy Program has convened Policy Summits in areas such as comparative effectiveness research (CER), risk evaluation and mitigation strategies (REMS), patient advocacy, off-label drug use and compendia, biosimilars, molecular testing, clinical pathways, and data needs.
NCCN will continue this initiative in 2013 with invitation-only summits focused on current policy topics. Details on NCCN's 2013 policy programs, as well as past summits, can be found below.
Please send any comments or questions regarding the NCCN Oncology Policy Program to firstname.lastname@example.org.
Joint Statement by NCCN Prostate Cancer Guidelines Panel, October 23, 2013
Medicare Beneficiaries: How do Accountable Care Organizations (ACOs) Impact your
Access to Cancer Care?
Patient Advocacy: Health Care Reform in 2013 and Beyond, November 2013
Measuring Quality in Oncology – Challenges and Opportunities, July 2013
Evolving Policy Issues in Oncology – Revisiting Biosimilars and Molecular Testing, April 2013
Patient Advocacy: Patient Perspectives Across the Cancer Care Continuum, November 2012
Data Needs in Oncology – Clinical, Regulatory, Coverage, and Policy Issues, October 2012
Equity in Cancer Care: Pathways, Protocols, and Guidelines, May 2012
Patient Advocacy, November 2011
Molecular Testing, July 2011
Biosimilars, April 2011
Off-Label Drug Use and Compendia, December 2010
Patient Advocacy, September 2010
Risk Evaluation and Mitigation Strategies, May 2010
Comparative Effectiveness Research, December 2009